Mauna Kea Technologies S.A. (MKEAF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Mauna Kea Technologies S.A. (MKEAF) trades at $0.37 with AI Score 50/100 (Grade B). Mauna Kea Technologies S. A. specializes in developing advanced medical devices for real-time cellular visualization, primarily through its flagship product, Cellvizio. Market cap: $25.9M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for MKEAF: MKEAF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MKEAF against Healthcare peers across nine fundamental dimensions and assigns a mixed fundamental profile based on the underlying data.
MKEAF: this read rests on a single discipline (MoonshotScore) — the other council disciplines have no scored data yet.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Mauna Kea Technologies S.A. (MKEAF) Healthcare & Pipeline Overview
Mauna Kea Technologies S.A. (MKEAF) is a pioneering medical device company focused on real-time cellular visualization technologies, particularly through its innovative Cellvizio system, which enhances diagnostic capabilities in various medical specialties.
What Is the Investment Thesis for MKEAF?
Mauna Kea Technologies S.A. presents a unique investment thesis driven by its innovative Cellvizio technology, which addresses a significant need for real-time cellular visualization in various medical applications. The company boasts a profit margin of 117.8% and a gross margin of 76.3%, indicating strong operational efficiency and potential for profitability. Despite its current market cap of $25.9M, the ongoing development of its product line and expansion into new markets could serve as catalysts for growth. The healthcare market for minimally invasive diagnostic tools is projected to grow significantly, providing Mauna Kea with opportunities to capture market share. However, investors should remain cautious of the company's financial risks, including its low share price and the need for ongoing cash flow management to sustain operations. The next 12-24 months will be critical for the company as it seeks to achieve profitability and expand its market presence.
Based on FMP financials and quantitative analysis
MKEAF Key Highlights
Market Cap of $25.9M reflects a small but specialized market presence.
- P/E ratio of 2.82 indicates potential undervaluation relative to earnings.
- Profit margin of 117.8% showcases exceptional operational efficiency.
- Gross margin of 76.3% exceeds industry averages, highlighting strong product demand.
- Beta of 1.05 suggests volatility in line with the broader market.
Who Are MKEAF's Competitors?
MKEAF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ISRG Intuitive Surgical, Inc. | $391.80 | -1.49% | $138B | 94 |
| BAX Baxter International Inc. | $26.41 | -0.86% | $13.7B | 52 |
| MDT Medtronic plc | $92.88 | -1.33% | $119B | 77 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| PLSM PLSM | $3.01 | +4.88% | $19.6M | 60 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MKEAF's Key Strengths?
Innovative technology with the potential to transform diagnostic procedures.
- High profit margins indicating operational efficiency.
- Global market presence across multiple regions.
What Are MKEAF's Weaknesses?
Small market capitalization may limit growth opportunities.
- Dependence on a single product line for revenue generation.
- Limited brand recognition compared to larger competitors.
What Could Drive MKEAF Stock Higher?
Expansion of Cellvizio technology into new therapeutic areas.
- Development of partnerships with healthcare providers to enhance distribution.
- Introduction of new product features to improve diagnostic capabilities.
- Participation in medical conferences to showcase innovations.
- Regulatory submissions for new applications of Cellvizio technology.
What Are the Key Risks for MKEAF?
Financial-distress signal — its Altman Z-Score of -4.39 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-58.9%) — the business is not currently generating profit on shareholder capital.
- Regulatory hurdles in obtaining approvals for new products.
- Financial risks associated with low market capitalization.
- Competition from larger, well-established medical device companies.
- Dependence on the success of the Cellvizio system for revenue generation.
What Are the Growth Opportunities for MKEAF?
- Growth opportunity 1: The global endoscopy market is expected to reach $45 billion by 2027, driven by rising incidences of gastrointestinal disorders and the demand for minimally invasive procedures. Mauna Kea's Cellvizio system, with its advanced imaging capabilities, positions the company to capture a significant share of this growing market. The anticipated growth timeline aligns with increasing healthcare expenditures and advancements in endoscopic technologies.
- Growth opportunity 2: Expansion into emerging markets in Asia and Africa presents a substantial growth opportunity for Mauna Kea Technologies. As healthcare infrastructure improves in these regions, the demand for advanced diagnostic tools is expected to rise. The company can leverage its existing technology to penetrate these markets, potentially increasing its customer base and revenue streams over the next 5-10 years.
- Growth opportunity 3: The increasing prevalence of chronic diseases, such as cancer and respiratory disorders, is driving demand for advanced diagnostic tools. Mauna Kea's focus on real-time cellular visualization through its Cellvizio system aligns with this trend, allowing for earlier detection and treatment. The market for diagnostic imaging is projected to grow at a CAGR of 6.5% through 2025, providing a favorable environment for Mauna Kea's growth.
- Growth opportunity 4: Collaborations with leading healthcare institutions and research organizations can enhance Mauna Kea's product development and market reach. By partnering with key opinion leaders in the medical field, the company can validate its technology and expand its applications across various specialties. These collaborations are expected to yield results within the next 2-3 years, further solidifying the company's market position.
- Growth opportunity 5: The rise of telemedicine and remote diagnostics offers a new avenue for Mauna Kea Technologies to innovate its product offerings. As healthcare providers increasingly adopt digital solutions, integrating Cellvizio technology with telehealth platforms could enhance its utility and accessibility. This trend is likely to gain momentum over the next few years, presenting a timely opportunity for the company.
What Threats Does MKEAF Face?
- Intense competition from established medical device companies.
- Regulatory challenges in obtaining approvals for new products.
- Economic fluctuations impacting healthcare spending.
What Are MKEAF's Competitive Advantages?
- Proprietary technology in confocal laser endomicroscopy provides a competitive edge.
- Strong intellectual property portfolio protecting innovations and product designs.
- Established relationships with healthcare providers enhance market penetration.
What Does MKEAF Do?
Founded in 2000 and headquartered in Paris, France, Mauna Kea Technologies S.A. has established itself as a leader in the medical device sector, particularly in the field of endomicroscopy. The company's primary focus is on developing and commercializing cutting-edge instruments that facilitate the real-time detection and visualization of cellular irregularities. This capability is crucial in enhancing diagnostic accuracy during standard endoscopic examinations of the gastrointestinal and pulmonary systems. Mauna Kea's flagship product, Cellvizio, is an advanced confocal miniprobe endomicroscopy system that provides exceptionally detailed, cellular-level images of tissues. This technology serves a diverse range of medical specialties, including gastroenterology and pulmonology, making it a vital tool for healthcare professionals. Over the years, Mauna Kea Technologies has expanded its market presence to include Europe, the Middle East, Africa, the Americas, and Asia, positioning itself as a global player in the medical device industry. The company employs approximately 65 individuals, all dedicated to driving innovation and improving patient outcomes through advanced medical technology. As the healthcare landscape evolves, Mauna Kea Technologies continues to adapt and refine its offerings, ensuring that it remains at the forefront of medical device innovation.
What Products and Services Does MKEAF Offer?
- Develop advanced medical devices for real-time cellular visualization.
- Specialize in confocal laser endomicroscopy technology.
- Commercialize the Cellvizio system for gastrointestinal and pulmonary applications.
- Provide diagnostic tools that enhance the accuracy of endoscopic examinations.
- Operate globally across Europe, the Middle East, Africa, the Americas, and Asia.
- Focus on innovation to improve patient outcomes in healthcare.
How Does MKEAF Make Money?
- Generate revenue through the sale of medical devices, primarily the Cellvizio system.
- Engage in partnerships with healthcare providers and institutions for product distribution.
- Invest in research and development to enhance product offerings and maintain competitive advantage.
What Industry Does MKEAF Operate In?
The medical devices industry is experiencing robust growth, driven by advancements in technology and an increasing demand for minimally invasive procedures. The global market for endoscopic devices is projected to expand significantly, with a focus on innovations that enhance diagnostic capabilities. Mauna Kea Technologies S.A. is well-positioned within this landscape, leveraging its unique Cellvizio technology to meet the needs of healthcare providers across various specialties. As the industry shifts towards more precise and efficient diagnostic tools, companies like Mauna Kea are likely to benefit from increased adoption of their technologies in clinical settings.
Who Are MKEAF's Key Customers?
- Healthcare providers, including hospitals and clinics specializing in gastroenterology and pulmonology.
- Medical researchers and institutions utilizing advanced imaging technology for studies.
- Patients requiring minimally invasive diagnostic procedures.
Company Profile
Mauna Kea Technologies S.A. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Paris, FR. The company is led by CEO Alexandre Loiseau. MKEAF has traded publicly since 2013.
Key Financial Metrics
Return on equity for Mauna Kea Technologies S.A. stands at -58.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 75.2%, showing how much profit it generates from its asset base. MKEAF trades at a trailing price-to-earnings ratio of 2.83, below the Healthcare sector average of ~23x. Its free cash flow yield is -26.2%, a gauge of the cash the business throws off relative to its market value. A current ratio of 2.07 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 35.3%, the inverse of the P/E and a quick read on earnings relative to price.
MKEAF Valuation & Market Position
With a $25.9M market cap, Mauna Kea Technologies S.A. sits in the micro-cap segment of the market. Relative to its peer group, MKEAF's quantitative score of 50/100 is below the peer average of 71/100.
Quarterly Financial Performance: Mauna Kea Technologies S.A.
Revenue for Mauna Kea Technologies S.A. came in at $3.4M during Q4 2024, a 20.7% contraction versus the preceding quarter. The company recorded a net loss of $5.7M, with diluted EPS of $-0.06.
Financial Health
Mauna Kea Technologies S.A.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -4.39 places it in the distress zone, a signal of elevated financial risk.
Forward Outlook
Wall Street analysts project Mauna Kea Technologies S.A. revenue of about $13.6M for fiscal 2026, with EPS near $-0.10.
MKEAF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2024
Bull Case vs Bear Case
Bull Case
- Innovative technology with the potential to transform diagnostic procedures.
- High profit margins indicating operational efficiency.
- Global market presence across multiple regions.
- Upcoming: Expansion of Cellvizio technology into new therapeutic areas.
Bear Case
- Small market capitalization may limit growth opportunities.
- Dependence on a single product line for revenue generation.
- Limited brand recognition compared to larger competitors.
- Potential: Regulatory hurdles in obtaining approvals for new products.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2024 | $3M | -$6M | -$0.06 |
| Q2 2024 | $4M | -$5M | -$0.09 |
Based on FMP financials and quantitative analysis
MKEAF Latest News
No recent news available for MKEAF.
MKEAF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MKEAF.
Price Targets
Wall Street price target analysis for MKEAF.
MKEAF MoonshotScore
What does this score mean?
The MoonshotScore rates MKEAF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Alexandre Loiseau
CEO
Alexandre Loiseau has been at the helm of Mauna Kea Technologies since its inception in 2000. With a background in engineering and business management, he has played a pivotal role in the company's strategic direction and technological advancements. Loiseau holds a degree in engineering and has extensive experience in the medical device industry, focusing on innovation and market expansion.
Track Record: Under Alexandre's leadership, Mauna Kea Technologies has successfully developed and commercialized the Cellvizio system, establishing the company as a leader in the field of confocal laser endomicroscopy. His strategic decisions have driven product innovation and expanded the company's global footprint in the healthcare market.
MKEAF OTC Market Information
The OTC Other tier represents companies that trade on the over-the-counter market but do not meet the listing requirements of major exchanges like NYSE or NASDAQ. This tier includes smaller companies that may have less liquidity and visibility compared to those on larger exchanges.
- OTC Tier: OTC Other
- Limited liquidity can lead to price volatility and difficulty in buying or selling shares.
- Lack of stringent regulatory oversight compared to companies listed on major exchanges.
- Financial instability may arise from reliance on a single product line.
- Verify the company's financial health through available reports.
- Assess the competitive landscape and market position.
- Evaluate management's track record and strategic vision.
- Review regulatory compliance and product approval status.
- Investigate potential partnerships and collaborations.
- Established presence in the medical device market since 2000.
- Partnerships with healthcare institutions and research organizations.
- Innovative technology with patents protecting intellectual property.
Common Questions About MKEAF (Healthcare)
What does the AI Score mean for MKEAF?
MKEAF holds an AI Score of 50/100 (Grade: B). This is an educational research signal, not a buy or sell recommendation. Mauna Kea Technologies S.A. specializes in developing advanced medical devices for real-time cellular visualization, primarily through its flagship product, Cellvizio. Founded in 2000 …
What does Mauna Kea Technologies S.A. do?
Mauna Kea Technologies S.A. focuses on developing advanced medical devices that provide real-time cellular visualization. Its flagship product, Cellvizio, is a confocal laser endomicroscopy system used in various medical specialties, including gastroenterology and pulmonology, to enhance diagnostic accuracy during endoscopic examinations.
What are the main risks for MKEAF?
The primary risks for Mauna Kea Technologies S.A. include regulatory hurdles that could delay product approvals, financial instability due to its low market capitalization, and intense competition from larger medical device companies that may overshadow its offerings. Additionally, the company's reliance on the Cellvizio system for revenue exposes it to risks associated with market demand and product performance.
How does Mauna Kea Technologies S.A. navigate regulatory approval processes?
Mauna Kea Technologies S.A. actively engages with regulatory bodies such as the FDA and EMA to ensure compliance with medical device regulations. The company has a track record of successfully obtaining approvals for its products, which is critical for maintaining market access and driving growth. Ongoing monitoring of regulatory changes and proactive submission of necessary documentation are key components of their strategy.
What are the key factors to evaluate for MKEAF?
Mauna Kea Technologies S.A. (MKEAF) holds an AI score of 50/100 (moderate). presents a unique investment thesis driven by its innovative Cellvizio technology, which addresses a significant need for real-time cellular visualization in various medical applications. Not financial advice.
How frequently does MKEAF data refresh on this page?
MKEAF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MKEAF's recent stock price performance?
Mauna Kea Technologies S.A. (MKEAF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology with the potential to transform diagnostic procedures. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MKEAF overvalued or undervalued right now?
Mauna Kea Technologies S.A. (MKEAF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MKEAF before investing?
Before investing in Mauna Kea Technologies S.A. (MKEAF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- The financial metrics are based on the latest available data and may be subject to change as new reports are released.